Millions of people live with chronic diseases for which there are few or no treatment options. This presents a major burden to individuals, healthcare services and society at large. ​

At Novo Nordisk, we want to change this. ​

We have a 100-year-long heritage of reducing limitations of life across the cardiometabolic spectrum, including diabetes and obesity. Now, we are expanding our commitment – reaching even more people with serious chronic diseases in areas of high unmet need across a number of different therapy areas. ​

We are focusing on areas of high unmet need because this is where we believe we can make the most difference.  But to do so demands the efforts of all of us.

That's why we're always on the hunt for top talent, right now within 3 different therapy areas: Cardiovascular Disease, Nonalcoholic steatohepatitis (NASH) and Alzheimer's Disease. ​Explore each therapy area below and take a step closer to a life-changing career.

Through science, data and innovation, we challenge our thinking to explore novel treatments, and by better understanding people living with these diseases, we strive to develop relevant solutions. ​

Join us in shaping the future direction of our company, all while improving the lives of millions of people living with chronic disease

Cardiovascular disease covers a wide range of diseases that combined represents one of the greatest health challenges of our time. Today, it is the leading cause of death globally,1 and yet, we still lack additional solutions to manage it. ​

It’s our mission to change this story. ​

At Novo Nordisk, we are determined to reduce the risk and burden of living with cardiovascular disease. Through science, data and innovation, we challenge our thinking to explore new treatments. By better understanding people living with cardiovascular disease, we strive to develop relevant solutions that support patients limited by this disease.​

Together, we are driving change in cardiovascular disease. Join us. 

Take the next step towards a life-changing career

  • Current open positions. We currently offer more than 1.000 career opportunities. See our open positions within the CVD right here 
  • Sign up for future positions: Sign up to get relevant opportunities straight to your inbox with our email job agent.
  • Follow us on LinkedIn. Get to know Novo Nordisk by following us on LinkedIn

Today around 100 million people are living with Alzheimer’s disease.2-5  This number is expected to triple by 2050.6 Alzheimer’s disease is a progressive neurodegenerative disease that slowly impairs cognition, and eventually the ability to carry out simple daily tasks, having a major impact on individuals, their loved ones and society more broadly.  ​

Despite this, there is currently no cure for Alzheimer’s disease, or any treatments available that can definitively  stop or slow disease progression.7-8

We're on a mission to change this. Raising awareness of early symptoms working to bring a treatment to market that will slow disease progression. ​

Join us to drive change in the fight against Alzheimer’s disease – bringing hope to millions of people. 

Nonalcoholic steatohepatitis (NASH) is a serious, progressive metabolic liver disease that affects millions of people worldwide – up to 6.5% of people globally9– and it is expected to increase in prevalence. This represents a great burden on individual patients, healthcare services and society as a whole ​

Due to challenges associated with diagnosis, non-specific symptoms, non-standardised identification and lack of regulatory approved treatment options, people living with NASH often remain undiagnosed and sub-optimally managed.​

At Novo Nordisk, we are committed to developing new treatment options for people living with NASH while supporting the advancement ​

of non-invasive diagnostics to address challenges in screening, diagnosing and monitoring prognosis. ​

Start your life-changing career today and join us in our mission to drive change for people living with NASH. 

  • Current open positions. We currently offer more than 1.000 career opportunities. See our open positions within NASH right here 
  • Sign up for future positions: Sign up to get relevant opportunities straight to your inbox with our email job agent.
  • Follow us on LinkedIn. Get to know Novo Nordisk by following us on LinkedIn

1. World Health Organisation. Cardiovascular diseases. Available from: https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds). Last accessed: January 2023. 

2. Busse A, Angermeyer MC and Riedel-Heller SG. Progression of mild cognitive impairment to dementia: a challenge to current thinking. Br J Psychiatry. 2006;189:399-404.​

3. Petersen RC. Mild Cognitive Impairment. Continuum (Minneap Minn). 2016;22:404-18.​

4. Alzheimer’s Society. Dementia UK Second Edition. Available from: http://eprints.lse.ac.uk/59437/1/Dementia_UK_Second_edition_-_Overview.pdf Last accessed: July 2021.​

5. Division UNP. World Population Prospects 2019. 2021.​

6. Wimo A, Guerchet M, Ali GC, et al. The worldwide costs of dementia 2015 and comparisons with 2010. Alzheimers Dement. 2017;13:1-7.​

7. El-Hayek YH, Wiley RE, Khoury CP, et al. Tip of the Iceberg: Assessing the Global Socioeconomic Costs of Alzheimer's Disease and Related Dementias and Strategic Implications for Stakeholders. J Alzheimers Dis. 2019;70:323-341.​

8. Alzheimer's Association. Alzheimer's Disease Facts and Figures. Available from: https://www.alz.org/media/documents/alzheimers-facts-and-figures.pdf Last accessed: July 2021.

9. Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016; 64:73-84.